HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
This is a clinical trial to study the use of Tadekinig alfa or placebo (medication) in the treatment of NLRC4 MAS mutation or XIAP deficiency.
Researching the causes of liver diseases and new ways to treat children with these disorders using a bench-to-bedside approach that integrates clinical care, clinical research, and basic science research.
